Endocrine complications in long-term survivors after allogeneic stem cell transplant

Seminars in Hematology

Volumn 49, Issue 1, 2012, Pages 66-72

  Gunasekaran, Uma ^a   Agarwal, Neena ^a   Jagasia, Madan H ^b   Jagasia, Shubhada M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; C PEPTIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOCALCIFEROL; FLUOROURACIL; GLUCOCORTICOID; HYPERGLYCEMIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TESTOSTERONE; ZOLEDRONIC ACID;

ADRENAL DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AVASCULAR NECROSIS; BLOOD CHEMISTRY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG USE; DYSLIPIDEMIA; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOPHYSIS DISEASE; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; THYROID CANCER; THYROID DISEASE; TREATMENT INDICATION; VITAMIN D DEFICIENCY;

ENDOCRINE SYSTEM DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SURVIVORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855384544     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.10.010     Document Type: Article

References (64)

1. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
2. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007, 109:1765-1772.
3. Griffith M.L., Jagasia M., Jagasia S.M. Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract 2010, 16:699-706.
4. Taskinen M., Saarinen-Pihkala U.M., Hovi L., Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000, 356:993-997.
5. Lorini R., Cortona L., Scaramuzza A., et al. Hyperinsulinemia in children and adolescents after bone marrow transplantation. Bone Marrow Transplant 1995, 15:873-877.
6. Majhail N.S., Challa T.R., Mulrooney D.A., Baker K.S., Burns L.J. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:1100-1107.
7. Griffith M.L., Jagasia M.H., Misfeldt A.A., Chen H., Engelhardt B.G., Kassim A., et al. Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:86-92.
8. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69. Association AD.
9. Griffith M.L., Savani B.N., Boord J.B. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010, 116:1197-1204.
10. Turchin A., Wiebe D.A., Seely E.W., Graham T., Longo W., Soiffer R. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant 2005, 35:85-89.
11. Subramanian S., Trence D.L. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 2007, 36:891-905.
12. Kobashigawa J.A., Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation 1997, 63:331-338.
13. Hoffmeister P.A., Hingorani S.R., Storer B.E., Baker K.S., Sanders J.E. Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:515-524.
14. Rizzo J.D., Wingard J.R., Tichelli A., Lee S.J., Van Lint M.T., Burns L.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006, 12:138-151.
15. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
16. Majhail N.S., Flowers M.E., Ness K.K., et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009, 43:49-54.
17. Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004, 109:3122-3131.
18. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
19. Anserini P., Chiodi S., Spinelli S., et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant 2002, 30:447-451.
20. Chatterjee R., Andrews H.O., McGarrigle H.H., et al. Cavernosal arterial insufficiency is a major component of erectile dysfunction in some recipients of high-dose chemotherapy/chemo-radiotherapy for haematological malignancies. Bone Marrow Transplant 2000, 25:1185-1189.
21. Molassiotis A., van den Akker O.B., Milligan D.W., Boughton B.J. Gonadal function and psychosexual adjustment in male long-term survivors of bone marrow transplantation. Bone Marrow Transplant 1995, 16:253-259.
22. Bakker B., Massa G.G., Oostdijk W., Van Weel-Sipman M.H., Vossen J.M., Wit J.M. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur J Pediatr 2000, 159:31-37.
23. Chatterjee R., Kottaridis P.D. Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies. Bone Marrow Transplant 2002, 30:629-635.
24. Chatterjee R., Kottaridis P.D., McGarrigle H.H., Linch D.C. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant 2002, 29:607-610.
25. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997, 82:2386-2390.
26. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:2536-2559.
27. Schimmer A.D., Quatermain M., Imrie K., et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol 1998, 16:2359-2363.
28. Schubert M.A., Sullivan K.M., Schubert M.M., et al. Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990, 5:425-430.
29. Salooja N., Szydlo R.M., Socie G., et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001, 358:271-276.
30. Piccioni P., Scirpa P., D'Emilio I., et al. Hormonal replacement therapy after stem cell transplantation. Maturitas 2004, 49:327-333.
31. Massenkeil G., Fiene C., Rosen O., Michael R., Reisinger W., Arnold R. Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia 2001, 15:1701-1705.
32. Joseph R.W., Alousi A., Konda B., et al. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 2011, 86:954-956.
33. Vitamin D and cancer: a report of the IARC Working Group on Vitamin D. International Agency for Research on Cancer (World Health Organization) Working Group Reports 2008.
34. Kananen K., Volin L., Laitinen K., Alfthan H., Ruutu T., Valimaki M.J. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005, 90:3877-3885.
35. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
36. Yao S., McCarthy P.L., Dunford L.M., et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008, 41:393-398.
37. Weilbaecher K.N. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000, 6:165-174.
38. Savani B.N., Donohue T., Kozanas E., et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:517-520.
39. Ebeling P.R. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 2009, 94:1483-1490.
40. Black D.M., Kelly M.P., Genant H.K., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
41. McAvoy S., Baker K.S., Mulrooney D., et al. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1231-1236.
42. Campbell S., Sun C.L., Kurian S., et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer 2009, 115:4127-4135.
43. Jagasia S., Misfeldt A., Griffith M., Jagasia M. Age and total-body irradiation in addition to corticosteroid dose are important risk factors for avascular necrosis of the bone. Biol Blood Marrow Transplant 2010, 16:1750-1751.
44. Al-Fiar F.Z., Colwill R., Lipton J.H., Fyles G., Spaner D., Messner H. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants. Bone Marrow Transplant 1997, 19:1019-1022.
45. Sanders J.E., Hoffmeister P.A., Woolfrey A.E., et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 2009, 113:306-308.
46. Ishiguro H., Yasuda Y., Tomita Y., et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004, 89:5981-5986.
47. Berger C., Le-Gallo B., Donadieu J., et al. Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant 2005, 35:991-995.
48. Tauchmanova L., Selleri C., De Rosa G., et al. Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med 2005, 118:664-670.
49. Aldouri M.A., Ruggier R., Epstein O., Prentice H.G. Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia. Br J Haematol 1990, 74:118-119.
50. Ishikawa F., Shigematsu H., Gondo H., Okamura T., Niho Y. Autoreactive antibodies following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998, 22:729-731.
51. Sigurdson A.J., Ronckers C.M., Mertens A.C., et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005, 365:2014-2023.
52. Cohen A., Rovelli A., Merlo D.F., et al. Risk for secondary throid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol 2007, 25:2449-2454.
53. Are C., Hsu J.F., Ghossein R.A., Schoder H., Shah J.P., Shaha A.R. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 2007, 14:3210-3215.
54. 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2007, 92:4485-4488.
55. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
56. May M.E., Carey R.M. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med 1985, 79:679-684.
57. Dickstein G., Arad E., Shechner C. Low-dose ACTH stimulation test. Endocrinologist 1997, 7:285-293.
58. Ackerman G.L., Nolsn C.M. Adrenocortical responsiveness after alternate-day corticosteroid therapy. N Engl J Med 1968, 278:405-409.
59. Nichols T., Nugent C.A., Tyler F.H. Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol Metab 1965, 25:343-349.
60. Graber A.L., Ney R.L., Nicholson W.E., Island D.P., Liddle G.W. Natural history of pituitary-adrenal recovery following long-term suppression with corticosteroids. J Clin Endocrinol Metab 1965, 25:11-16.
61. Orth D.N. Adrenal insufficiency. Curr Ther Endocrinol Metab 1994, 5:124-130.
62. Cohen A., Rovelli A., Bakker B., et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood 1999, 93:4109-4115.
63. Shinagawa T., Tomita Y., Ishiguro H., et al. Final height and growth hormone secretion after bone marrow transplantation in children. Endocr J 2001, 48:133-138.
64. Giorgiani G., Bozzola M., Locatelli F., et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995, 86:825-831.